Stockscreener 앱 받기
7.48
1.08%
0.08
시간 외 거래:
7.45
-0.03
-0.40%
전일 마감가:
$7.40
열려 있는:
$7.48
하루 거래량:
764.92K
Relative Volume:
0.68
시가총액:
$547.42M
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
-3.7588
EPS:
-1.99
순현금흐름:
$-64.37M
1주 성능:
+4.62%
1개월 성능:
-3.61%
6개월 성능:
+0.00%
1년 성능:
+123.28%
1일 변동 폭
$7.30
$7.57
1주일 범위
$6.89
$7.58
52주 변동 폭
$3.27
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
명칭
Mind Medicine Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
MNMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
7.48 | 547.42M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.24 | 121.11B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
740.01 | 81.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
638.33 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.58 | 31.52B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.39 | 28.35B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Mind Medicine Inc 주식(MNMD)의 최신 뉴스
Mind Medicine (MindMed) (NASDAQ:MNMD) Receives Outperform Rating from Oppenheimer - MarketBeat
MindMed doses first subject in trial of tablets for generalised anxiety disorder - Yahoo Finance
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - Morningstar
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment - Investing.com
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress - Business Wire
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
MindMed awarded Innovation Passport for MM120 - The Pharma Letter
Insider Buying: David Gryska Acquires Additional Shares of Mind Medicine Inc (MNMD) - GuruFocus.com
Mind Medicine director David Gryska acquires $17,925 in shares - Investing.com
Mind Medicine director David Gryska acquires $17,925 in shares By Investing.com - Investing.com Nigeria
MindMed gains UK Innovation Passport for GAD treatment - Investing.com
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) - Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - citybiz
MindMed appoints new VP of R&D Strategy - Investing.com
MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK
MindMed Announces New Employee Inducement Grants - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
Vera hires Jason Carter as chief legal officer - BioCentury
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
MindMed Advances Phase 3 Trials in Mental Health - TipRanks
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... - Yahoo Finance
Certain Restricted Stock Units of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
Certain Warrants of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
MindMed Reports Third Quarter 2024 Financial Results and Business Updates - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.1%What's Next? - MarketBeat
(MNMD) Trading Report - Stock Traders Daily
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
1.84%
자본화:
|
볼륨(24시간):